Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

11.5K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils03:03

Amyloid Fibrils

6.2K
6.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

699
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
699
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same author

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
Same author

Interconnected influences of diet, gut microbiome, and metabolome on cognition across three metabolomics platforms.

Research square·2026
Same author

Short T1 Fraction as a Marker of Myelin Content: Evidence from Postmortem MRI and Histology.

bioRxiv : the preprint server for biology·2026
Same author

Amygdala microstructural changes in subjective cognitive decline: A diffusion kurtosis and neurite orientation dispersion and density imaging study.

Journal of Alzheimer's disease : JAD·2026
Same author

Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration.

Acta neuropathologica·2026

Related Experiment Video

Updated: Dec 29, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.4K

APOE-amyloid interaction: Therapeutic targets.

Thomas Wisniewski1, Eleanor Drummond2

  • 1Departments of Neurology, Pathology and Psychiatry, Center for Cognitive Neurology, NYU School of Medicine, Science Building, Rm 1017, 435 East 30(th) Street, New York, NY 10016, USA.

Neurobiology of Disease
|February 7, 2020
PubMed
Summary

Alzheimer's disease (AD) lacks effective treatments. Targeting the Apolipoprotein E (APOE) and amyloid beta (Aβ) interaction shows promise for slowing AD progression and developing new therapies.

Keywords:
Apolipoprotein EBeta amyloidEarly onset ADImmunomodulationInteractionOligomersPathological chaperonePeptoidsTherapy

More Related Videos

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

12.2K
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

19.8K

Related Experiment Videos

Last Updated: Dec 29, 2025

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

12.4K
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

12.2K
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

19.8K

Area of Science:

  • Neurodegenerative diseases
  • Genetics of Alzheimer's disease
  • Pharmacological research

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no current cure.
  • The ε4 allele of Apolipoprotein E (APOE) is the primary genetic risk factor for late-onset AD.
  • The APOE-amyloid beta (Aβ) interaction is central to AD pathogenesis, influencing Aβ aggregation, clearance, and downstream pathologies.

Purpose of the Study:

  • To review the critical role of APOE in Alzheimer's disease (AD) pathogenesis.
  • To highlight promising therapeutic strategies targeting the APOE-Aβ interaction for AD treatment.

Main Methods:

  • Literature review of studies on APOE, Aβ, and AD pathogenesis.
  • Analysis of existing and emerging therapeutic approaches focused on the APOE-Aβ pathway.

Main Results:

  • APOE ε4 allele significantly increases AD risk.
  • APOE influences amyloid plaque formation, amyloid angiopathy, and tau pathology.
  • Targeting the APOE-Aβ interaction represents a novel therapeutic avenue for AD.

Conclusions:

  • Understanding the APOE-Aβ interaction is crucial for developing effective AD treatments.
  • Therapeutic strategies focusing on modulating APOE-Aβ interactions hold significant potential for combating Alzheimer's disease.